Pharma Biopharmaceuticals Finland Oy made a major breakthrough in the treatment of thrombocytopenia (low platelet count) with the development of efficacious biologically active Romiplostim (N-Plate(R) Biosimilar) production technology. Under the ownership of Pharma Biopharmaceuticals Finland Oy, Romiplostim has been developed to cure the patients suffering from chronic immune thrombocytopenia purpura (ITP) at the company’s Finland site in Oulu.
Romiplostim will be a Bliss for the Patients Suffering from Cancer
ITP has been a severe blood disorder detected by the increasing impaired and destruction of platelets, which can cause bleeding and serious bruising at times. Besides cancer lurking itself among patients, thrombocytopenia is often caused due to the radiation treatment or chemotherapy given to the patients. Complications such as low platelet count lead to bleeding, impacts surgical operations and even chemotherapy. Romiplostim will help the patients suffering from this serious disorder.
Post the manufacturing of the first batches of Romiplostim, Paras Biopharmaceuticals Finland Oy will reach to a position, where it will be able to meet the Good Manufacturing Practices (GMP) in the year 2019, under its Romiplostim biosimilar development program. The director of Biologics and Licensing opines that this novel drug will boost commercialization, besides reflecting positively on the healthcare industry.
Current Cure for ITP has been Tough on the Pockets of the Patients
The company states that they are currently engaged in analyzing the initial batches to evaluate comparability with the expectations of underpinning clinical trials and getting approvals for commercial supply of these drugs. The pervasiveness of ITP among a wide number of patients.
Inefficient processes apropos of drug production and expensive costs of drugs utilized for the treatment of ITP have been prevalent in the healthcare industry. The annual cost for the treatment of ITP diagnosed patient can soar up to $55250 USD. The new drug developed by Paras Biopharmaceuticals Finland Oy, the company intends to offer affordable treatment to the ITP-suffering patients.
About Paras Biopharmaceuticals Finland Oy
Paras Biopharmaceuticals Finland Oy was established in 2012 in Finland with a team of experienced technologists, bioprocess engineers, and protein scientists. The company is well-equipped with advanced facilities to produce recombinant therapeutics products.
Its major operating areas comprises of – advancement and licensing of Biosimilars, recombinant bioprocess enzymes and microbial biologics manufacturing and contract development. The company has put its endeavors for clinical developments in conjunction with marketing collaboration for many of the Biosimilars.
Mr. Shambhu Nath Jha is a seasoned consultant and researcher. His research papers have been published in reputed websites and trade journals. His interests include philosophy and history.